|
18 Nov 2025
|
Supriya Lifescience
|
Deven Choksey
|
744.45
|
850.00
|
787.35
(-5.45%)
|
14.18 |
Accumulate
|
|
|
We expect growth momentum to sustain over the coming quarters, supported by steady demand across regulated markets, scale-up of the Module E facility, and a stronger mix from high-value therapies.
|
|
22 Aug 2025
|
Supriya Lifescience
|
Deven Choksey
|
744.45
|
800.00
|
695.10
(7.10%)
|
Target met |
Buy
|
|
|
We have revised our FY26E/FY27E EPS estimates by -3.8%/+0.3% primarily to reflect miss in the Q1FY26 performance, and higher depreciation expenses, however, FY27 numbers are intact with rising regulated market share, enhanced backward integration, scale-up of the DSM contract, and new launches such as contrast media and ADHD APIs.
|
|
22 Dec 2023
|
Supriya Lifescience
|
SBI Securities
|
744.45
|
309.00
|
297.05
(150.61%)
|
Target met |
Accumulate
|
|
|
SLL has a niche product basket of 38 APIs with presence in therapeutic areas of Analgesics, Anti-histamine, vitamins, anti-asthmatics, anti-allergic and anti-malarial. The company has tied up with
Kalinga Institute of Technology for development of GelHeal and Quickblue Oral Kit.
|
|
16 Dec 2021
|
Supriya Lifescience
|
ICICI Securities Limited
|
744.45
|
|
|
|
IPO Note
|
|
|
Supriya has been the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India, contributing to 45-50% and 60-65%, respectively, of the API exports from India, between FY17 and FY21. SLL is among the largest exporters of Salbutamol Sulphate in India contributing to...
|
|
16 Dec 2021
|
Supriya Lifescience
|
Hem Securities
|
744.45
|
|
|
|
IPO Note
|
|
|
Supriya Lifescience is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients (APIs), with a focus on research and development. As of October 31, 2021, company have niche product offerings of 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic,...
|
|
15 Dec 2021
|
Supriya Lifescience
|
Ashika Research
|
744.45
|
|
|
|
IPO Note
|
|
|
Public issue of 2,55,47,445 Equity shares of Face value Total Public 2 each, (Comprising of fresh issue of 72,99,270 Equity Shares* (Rs. 200 cr.) and Offer for Sale of 1,82,48,175 Equity Shares* (Rs. 500 cr.) by Selling Shareholder)....
|
|
15 Dec 2021
|
Supriya Lifescience
|
Ventura
|
744.45
|
|
|
|
IPO Note
|
|
|
|
|
15 Dec 2021
|
Supriya Lifescience
|
Angel Broking
|
744.45
|
|
|
|
IPO Subscribe
|
|
|
Supriya Lifescience Limited was incorporated in March 2008 by Satish Waman Wagh. Company is one of the key Indian manufacturers and suppliers of active pharmaceutical ingredients (APIs). Supriya Lifescience Limited focus on research and development along with this company focus is on diverse therapeutic areas and niche products. Company has niche product offerings of 38
|
